Trial · NCT06293300
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in photophobia measured by Numerical Rating Scale | Baseline, 6-weeks post-intervention, and 12-weeks post-intervention. | The change in numerical rating of average photophobia during the past week, ranging from 0 (for "no ocular pain") to 10 ("the most intense ocular pain imaginable"). |
| Primary | Change in visual photosensitivity thresholds (VPT) measured Ocular Photosensitivity Analyzer (OPA) | Baseline, 6-weeks post-intervention, and 12-weeks post-intervention. | The change in the OPA visual photosensitivity thresholds, ranging from 0 to 4.51 log lux, with a lower VPT indicating less tolerance to light or increased light sensitivity. |
| Secondary | Change in severity of visual photosensitivity symptoms measured by Visual Light Sensitivity Questionnaire-8 (VLSQ-8) | Baseline, 6-weeks post-intervention, and 12-weeks post-intervention. | Total score ranging from 8 to 40, with a higher score indicating more visual photosensitivity symptom severity. |
| Secondary | Change in severity of neuropathic ocular pain symptoms measured by Neuropathic Pain Symptom Inventory Questionnaire, modified for the Eye (NPSI-Eye). | Baseline, 6-weeks post-intervention, and 12-weeks post-intervention. | Total score ranging from 0 to 100, with higher scores reflecting greater neuropathic ocular pain symptom severity. |
| Secondary | Change in visual function related to activities of daily living measured by Visual Function Questionnaire-25 (VFQ-25) | Baseline, 6-weeks post-intervention, and 12-weeks post-intervention. | Total score ranging from 0 to 100, with higher scores indicating better quality of life. |
| Secondary | Change in migraine symptom severity score measured by in Migraine Symptom Severity Score (MSSS) | Baseline, 6-weeks post-intervention, and 12-weeks post-intervention. | Total score ranging from 0 to 21, with higher scores indicating greater migraine severity. |
| Secondary | Change in impact of headaches on daily life measured by Headache Impact Test (HIT)-6 | Baseline, 6-weeks post-intervention, and 12-weeks post-intervention. | Total score ranging from 36 to 78, with higher scores indicating greater impact of headaches have on a person's ability to function on the job, at school, at home and in social situations. |
| Secondary | Change in dry eye symptoms measured by the Dry Eye Questionnaire 5 (DEQ 5) | Baseline, 6-weeks post-intervention, and 12-weeks post-intervention. | Total score ranging from 0 to 22, with higher scores indicating more dry eye symptoms. |
| Secondary | Change in ocular surface disease index measured by the Ocular Surface Disease Index (OSDI) | Baseline, 6-weeks post-intervention, and 12-weeks post-intervention. | Total score ranging from 0 to 100, will be administered to assess dry eye symptoms, with higher scores indicating more dry eye symptoms and impact on daily activities. |
| Secondary | Change in pain intensity rating of aftersensations (AS) to repeated heat stimulation on the forehead measure by quantitative sensory testing (QST) | Baseline, 6-weeks post-intervention, and 12-weeks post-intervention. | QST methodology will be used to measure the severity of painful sensations that remain present 15 seconds after presentation of 10 one-second presentations (each separated by one second) of a noxious stimulus to the skin of the forehead. Ratings of the "intensity of pain" on a 0 to 100 numerical rating scale (0 = "no pain"; 100 = "most intense pain imaginable") will be recorded for these aftersensations. |
| Secondary | Change in temporal summation (TS) of heat pain on the forehead measure by quantitative sensory testing (QST) | Baseline, 6-weeks post-intervention, and 12-weeks post-intervention. | QST methodology will be used to measure the increase in pain intensity ratings that occur when repeated noxious stimuli are presented in rapid succession (i.e., temporal summation; TS). Ratings of the "intensity of pain" on a 0 to 100 numerical rating scale (0 = "no pain"; 100 = "most intense pain imaginable"). TS at each study time point will be determined by subtracting the rating of pain intensity at its peak during the rapid train of one-second noxious heat stimuli from the rating of pain intensity after a single one-second heat stimulus of the same temperature. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06293300/registered